Abstract
Ursolic acid (3β-hydroxy-urs-12-en-28-oic acid) isolated from many medicinal plants has diverse pharmacologically important properties, including strong anti-inflammatory activity. However its interaction with proinflammatory PLA2 is not known. Ursolic acid inhibited secretory PLA2 (sPLA2) enzymes purified from Vipera russelli, Naja naja venom and human pleural fluid and synovial fluid. IC50 values determined for these enzymes ranged from 12 to 18 μM. Group II secretory PLA2 from both venoms & human inflammatory source were found to be sensitive to inhibition in comparison with group I cobra venom sPLA2. Variation in Ca2+ concentration from 2.5 -15 mM did not alter the level of inhibition. Similarly sPLA2 inhibition by ursolic acid is independent of substrate concentration. Ursolic acid interacts with purified venom sPLA2 enzymes and enhances relative fluorescence intensity in a dose dependent manner. In the presence of ursolic acid apparent shift in the far UV-CD spectra of sPLA2 was observed, indicating a direct interaction with the enzyme and formation of enzyme-ursolic acid complex. This complex results in irreversible inhibition of sPLA2 as evident by dialysis study. Inhibition of sPLA2 induced mouse paw edema and indirect hemolytic activity confirmed its sPLA2 inhibitory activity in vivo and in situ respectively. These studies revealed that the strong anti-inflammatory activity of ursolic acid is by inhibiting sPLA2 enzymes.
Keywords: hemolytic activity, Edema, fluorescence spectroscopy, enzyme-ursolic acid complex, Dialysis
Current Topics in Medicinal Chemistry
Title: Group IIA Secretory PLA2 Inhibition by Ursolic Acid: A Potent Anti-Inflammatory Molecule
Volume: 7 Issue: 8
Author(s): A. Nataraj, C. D. Raghavendra Gowda, R. Rajesh and B. S. Vishwanath
Affiliation:
Keywords: hemolytic activity, Edema, fluorescence spectroscopy, enzyme-ursolic acid complex, Dialysis
Abstract: Ursolic acid (3β-hydroxy-urs-12-en-28-oic acid) isolated from many medicinal plants has diverse pharmacologically important properties, including strong anti-inflammatory activity. However its interaction with proinflammatory PLA2 is not known. Ursolic acid inhibited secretory PLA2 (sPLA2) enzymes purified from Vipera russelli, Naja naja venom and human pleural fluid and synovial fluid. IC50 values determined for these enzymes ranged from 12 to 18 μM. Group II secretory PLA2 from both venoms & human inflammatory source were found to be sensitive to inhibition in comparison with group I cobra venom sPLA2. Variation in Ca2+ concentration from 2.5 -15 mM did not alter the level of inhibition. Similarly sPLA2 inhibition by ursolic acid is independent of substrate concentration. Ursolic acid interacts with purified venom sPLA2 enzymes and enhances relative fluorescence intensity in a dose dependent manner. In the presence of ursolic acid apparent shift in the far UV-CD spectra of sPLA2 was observed, indicating a direct interaction with the enzyme and formation of enzyme-ursolic acid complex. This complex results in irreversible inhibition of sPLA2 as evident by dialysis study. Inhibition of sPLA2 induced mouse paw edema and indirect hemolytic activity confirmed its sPLA2 inhibitory activity in vivo and in situ respectively. These studies revealed that the strong anti-inflammatory activity of ursolic acid is by inhibiting sPLA2 enzymes.
Export Options
About this article
Cite this article as:
Nataraj A., Raghavendra Gowda D. C., Rajesh R. and Vishwanath S. B., Group IIA Secretory PLA2 Inhibition by Ursolic Acid: A Potent Anti-Inflammatory Molecule, Current Topics in Medicinal Chemistry 2007; 7 (8) . https://dx.doi.org/10.2174/156802607780487696
DOI https://dx.doi.org/10.2174/156802607780487696 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Role for the Complement System in Rheumatoid Arthritis
Current Pharmaceutical Design Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Understanding Mouse Skin Carcinogenesis through Transgenic Approaches
Current Genomics Importance of Iron and Iron Metabolism in Nonalcoholic Fatty Liver Disease
Mini-Reviews in Medicinal Chemistry Hepatitis C Treatment in Patients with Drug Addiction: Clinical Management of Interferon-Alpha-Associated Psychiatric Side Effects
Current Drug Abuse Reviews Virgin Olive Oil and Hypertension
Current Vascular Pharmacology Challenges in the Discovery and Optimization of mGlu2/4 Heterodimer Positive Allosteric Modulators
Letters in Drug Design & Discovery Copper Complexes of Bioactive Ligands with Superoxide Dismutase Activity
Mini-Reviews in Medicinal Chemistry The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments
Current Neuropharmacology Hepatitis C Virus: Efficacy of New DAAs Regimens
Infectious Disorders - Drug Targets NOD-Like Receptors: A Tail from Plants to Mammals Through Invertebrates
Current Protein & Peptide Science Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen Delivery
Current Drug Targets - Infectious Disorders Highly Pure Phospholipids Based Brain Docosahexaenoic Acid Transporters
Recent Patents on CNS Drug Discovery (Discontinued) Successful Screening of Large Encoded Combinatorial Libraries Leading to the Discovery of Novel p38 MAP Kinase Inhibitors
Combinatorial Chemistry & High Throughput Screening Inflammatory Biomarkers for Mood Disorders - A Brief Narrative Review
Current Pharmaceutical Design Allelic Variations in CYP2D6 Gene and Susceptibility to Cervical Cancer
Drug Metabolism Letters Polysaccharide-K (PSK) in Cancer - Old Story, New Possibilities?
Current Medicinal Chemistry The Effect of Lupane Triterpenoids (Dipteryx alata Vogel) in the in vitro Neuromuscular Blockade and Myotoxicity of two Snake Venoms
Current Organic Chemistry Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Strategies to Diminish the Ab Load in Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents